Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,014.59 USD

1,014.59
797,508

-25.68 (-2.47%)

Updated Oct 3, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Inovio Pharmaceuticals, Inc. (INO) reported loss of 31 cents for the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 34 cents.

    Arpita Dutt headshot

    Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death

    by Arpita Dutt

    Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.

      Regeneron Pharmaceuticals (REGN) Shares March Higher, Can It Continue?

      by Zacks Equity Research

      As of late, it has definitely been a great time to be an investor in Regeneron Pharmaceuticals Inc (REGN).

        Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene

        by Zacks Equity Research

        Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene

          Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates

          by Zacks Equity Research

          Regeneron Pharmaceuticals, Inc. (REGN) reported first-quarter 2017 results wherein earnings missed estimates while revenues beat expectations.

            Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss

            by Zacks Equity Research

            Ophthotech Corporation (OPHT) reported first-quarter 2017 loss of $1.20 per share, narrower than the Zacks Consensus Estimate of a loss of $1.31 but wider than the year-ago loss of $1.03

              Ekta Bagri headshot

              Regeneron (REGN) Q1 Earnings Misses Estimates

              by Ekta Bagri

              Regeneron???s first-quarter 2017 earnings missed expectations. Our consensus called for EPS of $2.50 and the company reported EPS of $2.16

                Kevin Cook headshot

                5 Healthcare Innovators I'm Still Buying

                by Kevin Cook

                When you think long-term about the megatrends in healthcare, it makes picking winners easier

                  What's in Store for Adverum (ADVM) in Q1 Earnings?

                  by Zacks Equity Research

                  Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.

                    Madeleine Johnson headshot

                    After Gilead Earnings, Buy These Biotech Stocks

                    by Madeleine Johnson

                    Shares of Gilead Sciences (GILD) are down about 2.6% in midday trading Wednesday after the biotech giant's first-quarter sales fell short of analyst estimates yesterday, leaving investors disappointed.

                      Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More

                      by Zacks Equity Research

                      Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.

                        Arpita Dutt headshot

                        Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update

                        by Arpita Dutt

                        Earnings were in focus this week with companies like Amgen (AMGN), Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.

                          Arpita Dutt headshot

                          6 FDA Events to Watch Out for in May 2017

                          by Arpita Dutt

                          Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.

                            Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?

                            by Zacks Equity Research

                            Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.

                              Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

                              by Zacks Equity Research

                              Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased

                                Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates

                                by Zacks Equity Research

                                Seattle Genetics, Inc. (SGEN) reported a loss of 42 cents per share for the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 41 cents and the year-ago loss of 15 cents per share.

                                  Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

                                  by Zacks Equity Research

                                  Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.

                                    Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline

                                    by Zacks Equity Research

                                    Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

                                      by Arpita Dutt

                                      Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.

                                        5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now

                                        by Zacks Equity Research

                                        Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback

                                          by Arpita Dutt

                                          Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.

                                            Regeneron's Evinacumab Gets Breakthrough Therapy by FDA

                                            by Zacks Equity Research

                                            Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has granted Breakthrough Therapy Designation status to ievinacumab for the treatment patients with Homozygous Familial Hypercholesterolemia.

                                              Arpita Dutt headshot

                                              4 FDA Decisions to Watch Out for in Apr 2017

                                              by Arpita Dutt

                                              Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.

                                                Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

                                                by Zacks Equity Research

                                                Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

                                                  Arpita Dutt headshot

                                                  Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study

                                                  by Arpita Dutt

                                                  Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.